STANLEY H APPEL, M.D.
Neurology at Fannin, Houston, TX

2006027, Dec 14, 2006

Apr 26, 2006

11/411659

Ira Goldknopf - The Woodlands TX, US
Essam Sheta - The Woodlands TX, US
Stanley Appel - Houston TX, US
Jennifer Bryson - The Woodlands TX, US
Lemuel Moye - Houston TX, US
Albert Yen - Houston TX, US
Brian Folsom - Chaska MN, US
Miguel Mosqueda - Willis TX, US

Power3 Medical Products, Inc. - The Woodlands TX

G01N 27/26

204601000

The present invention is an assay for determining if a patient has a neuromuscular disease. The method comprises collecting a biological sample from a patient, separating the proteins present in the biological sample, quantitating a panel of proteins by proteomic techniques, analyzing the quantity of the protein panel using biostatistics, and determining whether or not the patient has a neuromuscular disease based on the statistical analysis of the results.

4699875, Oct 13, 1987

Aug 23, 1985

6/769203

Stanley H. Appel - Houston TX

Baylor College of Medicine - Houston TX

C12D 100

435 4

The present invention is based on the discovery that amyotrophic lateral sclerosis (ALS), Parkinson disease and Alzheimer disease are due to lack of a disorder-specific neurotrophic hormone. Diagnosis is accomplished by assaying hormones specific for a particular neuronal network or system: the motor neurotrophic hormones from muscle in the motor neural system are used to diagnose and treat ALS, dopamine neurotrophic hormones from striatum in the migrostriatal neural system are used to diagnose and treat parkinsonism, and cholinergic neurotrophic hormones released from the cortex and hippocampus which are specific for cholinergic neorons of the nucleus basalis and septal nucleus are used to diagnose and treat Alzheimer's disease. With tissue culture, the presence or absence of specific neurotrophic hormones can be assessed in ALS, parkinsonism, and Alzheimer disease. If there is a deficiency, extracted and purified neurotrophic hormones specific to the particular neuronal network or system can be injected in ALS and Alzheimer disease and in parkinsonism.

4701407, Oct 20, 1987

Aug 23, 1985

6/769861

Stanley H. Appel - Houston TX

Baylor College of Medicine - Houston TX

C12Q 100

435 4

The present invention is based on the discovery that amyotrophic lateral sclerosis (ALS), Parkinson disease and Alzheimer disease are due to lack of a disorder-specific neurotrophic hormone. Diagnosis is accomplished by assaying hormones specific for a particular neuronal network or system: the motor neurotrophic hormones from muscle in the motor neural system are used to diagnose and treat ALS, dopamine neurotrophic hormones from striatum in the nigrostriatal neural system are used to diagnose and treat parkinsonism, and cholinergic neurotrophic hormones released from the cortex and hippocampus which are specific for cholinergic neurons of the nucleus basalis and septal nucleus are used to diagnose and treat Alzheimer's disease. With tissue culture, the presence or absence of specific neurotrophic hormones can be assessed in ALS, parkinsonism, and Alzheimer disease. If there is a deficiency, extracted and purified neurotrophic hormones specific to the particular neuronal network or system can be injected in ALS and Alzheimer disease and in parkinsonism.

4923696, May 8, 1990

Apr 22, 1988

7/179229

Stanley H. Appel - Houston TX
Kenneth W. Vaca - Houston TX

Baylor College of Medicine - Houston TX

A61K 3702

424548

The present invention is based on the discovery that amyotrophic lateral sclerosis (ALS), Parkinson disease and Alzheimer disease are due to lack of disorder-specific neurotrophic factors. Specific neurotrophic factors of. about. 20-22 kD and. about. 16-18 kD have been isolated from rat and human skeletal motor neurons, respectively, and purified. With tissue culture, the presence or absence of the specific neurotrophic factors provided herein can be assessed in ALS. If there is a deficiency, extracted and purified neurotrophic factors specific to the motor neuronal network or system can be administered to ALS-affected individuals.

2006011, Jun 1, 2006

Jan 19, 2005

11/038753

Ira Goldknopf - The Woodlands TX, US
Essam Sheta - The Woodlands TX, US
Stanley Appel - Houston TX, US
Ericka Simpson - Pearland TX, US
Albert Yen - Pearland TX, US

Power3 Medical Products, Inc. - The Woodlands TX

A61K 38/17, G01N 33/53, C07K 14/705, C07K 16/28

435007100, 514002000, 530350000, 530388220

The present invention relates to a biomarker for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), and Parkinson's (PD) disease. More particularly, the present invention relates to the identification of an acetyl-LDL receptor related protein as a biomarker useful for the detection, diagnosis, and differentiation of neurodegenerative disease, including but not limited to ALS, AD, and PD.

5851783, Dec 22, 1998

Feb 13, 1995

8/388179

Stanley H. Appel - Houston TX
R. Glenn Smith - Houston TX
Enrico Stefani - Houston TX

Baylor College of Medicine - Houston TX

G01N 33543, G01N 33545, G01N 33564, G01N 33567

435 792

A method and kit are described that are useful in the diagnosis of amyotrophic lateral sclerosis or the evaluation of its progression. According to the method, a purified voltage-sensitive calcium channel complex is contacted with a biological fluid obtained from a person suspected of having, or known to have, amyotrophic lateral sclerosis. The voltage-sensitive calcium channel is of a type that ALS sera selectively reacts with. The reaction takes place for a time and under conditions sufficient for the calcium channel complex and anti-calcium channel complex antibodies that may be present in the biological fluid to form an antigen/antibody complex. The presence or absence of the antigen/antibody complex is then determined.

5017375, May 21, 1991

May 18, 1987

7/052087

Stanley H. Appel - Houston TX
Yasuko Tomozawa - Houston TX

Baylor College of Medicine - Houston TX

A61K 3702, A61K 3534

424570

The present invention is based on the discovery that amyotrophic lateral sclerosis (ALS), Parkinson disease and Alzheimer disease are due to lack of a disorder-specific neurotrophic hormone or factor. Diagnosis is accomplished by assaying factors specific for a particular neuronal network or system; for example, dopamine neutotrophic hormones from striatum or caudate-putamen in the nigrostriatal dopaminergic neural system are used to diagnose and treat parkinsonism. With tissue culture, the presence or absence of spacific neurotrophic factos can be assessed in ALS, parkinsonism, and Alzheimer disease. If there is a deficiency, extracted and purified neurotrophic factors specific to the particular neuronal network or system can be injected into a patient having ALS, Alzheimer disease or parkinsonism for treatment of the disease.

2007001, Jan 25, 2007

Jul 17, 2006

11/487715

Ira Goldknopf - The Woodlands TX, US
Essam Sheta - The Woodlands TX, US
Brian Folsom - Chanhassen MN, US
Stanley Appel - Houston TX, US
Albert Yen - Pearland TX, US
Ericka Simpson - Pearland TX, US

Power3 Medical Products, Inc. - The Woodlands TX

B01D 57/02

204461000

The invention relates to an assay for discriminating between amyotrophic lateral sclerosis (ALS) patients and patients with ALS-like disorders that express symptoms like ALS. The method is based on the use of 2-dimensional (2D) gel electrophoresis to separate the complex mixture of proteins found in blood serum, the quantitation of a group of identified biomarkers, and the biostatistical analysis of the concentration of the identified biomarkers to differentiate patients having ALS from patients having other ALS-like disorders.

2007004, Feb 22, 2007

Aug 14, 2006

11/503881

Ira Goldknopf - The Woodlands TX, US
Essam Sheta - The Woodlands TX, US
Brian Folsom - Chanhassen MN, US
Stanley Appel - Houston TX, US
Albert Yen - Pearland TX, US

G01N 33/53

435007100, 204450000

The invention relates to an assay for discriminating between Alzheimer's disease (AD) patients, patients with AD-Like disorders that express symptoms like AD, and non-demented age-matched controls (Normal). The method is based on the use of 2-dimensional (2D) gel electrophoresis to separate the complex mixture of proteins found in blood serum, the quantitation of a group of identified biomarkers, and the biostatistical analysis of the concentration of the identified biomarkers to differentiate patients having AD from Normals and patients having other AD-Like disorders.